GE Healthcare Unveils New AI and Digital Technologies and Solutions to Help Solve Healthcare’s Most Pressing Problems

GE Healthcare | November 29, 2021

GE Healthcare Unveils New AI and Digital Technologies and Solutions to Help Solve Healthcare’s Most Pressing Problems

At the Radiological Society of North America’s (RSNA) 2021 Annual Meeting, GE Healthcare unveiled around 60 innovative technology solutions spanning the healthcare spectrum including patient screening, diagnostics, therapy planning, guidance, and monitoring. Amidst a global pandemic and mounting pressure on the industry, the company accelerated innovations underpinned by artificial intelligence (AI) and digital solutions to help transform healthcare delivery, making it easier and more efficient for clinicians and health systems, and more personalized and precise for patients.

The pandemic exposed the fragility of the global healthcare system, creating an urgent need for technology and solutions that help clinicians manage seriously ill COVID-19 patients, advanced diseases – such as cancer and heart disease – a backlog in non-urgent care, and an ageing population, while battling burnout and workforce shortages.

With these circumstances in mind, GE Healthcare is proud to introduce technologies and solutions at #RSNA21 that help healthcare systems:

  • Increase efficiency and productivity;
  • Reduce clinician burnout;
  • Empower clinicians with AI and analytics when, where and how they need it;
  • Create a more resilient and sustainable healthcare industry; and
  • Increase access to care.

“Our goal is to make healthcare more human by breaking down barriers so clinicians can work at the top of their game, healthcare systems can operate more efficiently, and patients can get the best and most personalized care possible. Healthcare is at a turning point and at GE Healthcare we are using our clinical expertise and know-how to deliver innovative technologies and solutions that help solve healthcare’s most pressing problems, advance precision health and improve patient lives.”

Kieran Murphy, president & CEO, GE Healthcare

Transforming healthcare through imaging technologies and digital offerings

Over the last year and a half, the industry has embraced technological innovation. What was once considered “futuristic” is now fundamental. In an environment where clinical expertise, regulatory know-how and speed matter, GE Healthcare rose to the challenge. Working alongside clinicians and care teams to understand the most pressing needs of radiologists and hospital administrators, the company innovated new solutions, leveraging its healthcare-specific intelligence platform, Edison, to help providers achieve greater efficiency, reduce errors, increase speed to appropriate treatments, and increase access to care.

To this end, GE Healthcare developed the following new AI-powered, automated and data-driven solutions to help encourage greater diagnostic confidence, ease the burden of care and improve workflow for healthcare systems around the world:

  • SIGNA Hero is named for our heroes on the frontlines, who continue to care for seriously ill patients as well as a backlog in non-urgent care – all the while battling burnout and workforce shortages. The new 3.0T MRI system offers new workflows and AIR Recon DL enhancements designed to help our heroes on the frontlines address some of today’s most pressing healthcare needs: enhanced productivity, patient comfort, and sustainabilityii.
  • SIGNA Artist Evo enables healthcare systems to modernize their legacy 1.5T narrow 60 cm bore MR systems to 1.5T, 70 cm bore systems, accommodating more patients of different shapes and sizes. Furthermore, the company’s patented flexible AIR Coils design and AIR Recon DL image reconstruction help provide clearer, sharper and more detailed images faster – enabling shorter patient setup times and reducing table time.
  • Revolution Apex platform provides exceptional image quality and low dose scanning for routine and challenging cases in many care areas with optimized clinical capabilities, built-in scalability and upgradability options.
  • Allia Platform is designed to enhance user experience, improve workflow efficiency and increase the adoption of advanced image guidance in daily practice – all important factors in today’s constrained healthcare environment. In addition to personalizing the Interventional or hybrid operating room with just one click of the user interface, leveraging the Edison platform, the system also harnesses the power of AI with AutoRightv – an advanced AI-based interventional image chain – and Liver ASSIST Virtual Parenchymavi,vii– a 3D visualization software solution designed to provide AI-based virtual parenchymography to help clinicians simulate injections dynamically and perform liver embolization procedures with confidence.
  • AMX Navigate represents GE Healthcare’s latest in portable x-ray technology with a new Zero Click Exam workflow solution and power-assisted Free Motion telescoping column to reduce lift force by an estimated 70 percentviii, helping to decrease X-ray technologist strain . The rugged reliability of the AMX Navigate helps ensure it is ready to perform at the bedside of the patient.
  • Critical Care Suite 2.0 offers a collection of AI algorithms embedded on a mobile x-ray device for case prioritization, automated measurements, and quality control. For the past year, the suite’s AI algorithm to help clinicians assess Endotracheal Tube (ETT) placements has helped clinicians care for an influx of critically ill COVID-19 patients who required ventilation under the FDA COVID-19 imaging guidance. Now, Critical Care Suite 2.0 has received full Food and Drug Administration (FDA) 510(k) clearance.
  • Vscan Air provides clinicians with quick insights at the point of care at a time when they need it most. This wireless and pocket-sized ultrasound device provides exceptionally clear image quality, whole-body scanning capabilities, and intuitive software - all in the palm of the clinician’s hand. A dual-probe enables whole-body scanning – with the flip of the wireless dual probe (for deep and shallow scanning) and a push of a button to capture images. Vscan Air offers a high-performance ultrasound machine in a lightweight, portable device designed to improve patient experience and access to ultrasound technology – involving patients by sharing real-time image sharing as simple as see, snap, send.
  • Enterprise Imaging in the Cloud delivers the power of technology in a smart, digital ecosystem giving radiologists easy and seamless access to GE Healthcare’s latest AI-based tools, data and intelligent technology for visualization, diagnostics and workflow as well as third party algorithms – from anywhere, anytimeix,x. The solution is cloud-based, enabling healthcare systems to manage upgrades instantly and digitally, with little to no new hardware or on-site IT team required.
  • Digital Expert Access is a real-time virtual collaboration solution that is integrated into imaging devices. With imaging experts in short supply and high demand and imaging moving beyond hospital campuses, Digital Expert Access allows sharing of expertise, best practices, and in-the-moment advice, as well as remote console control – all from a distance.
  • ulrichINJECT CT Motion uses automated syringeless technology to support workflow efficiencies. The injector, now approved with RIS/PACS integration, removes the need for manual syringe filling which may minimize examination preparation time and minimize contrast media waste.

A partner of choice creating and investing in new possibilities for the healthcare industry

As innovators, integrators and clinical experts, GE Healthcare is aligning its products and solutions across care pathways, such as oncology, to create end-to-end solutions.

The company is working with industry leaders, such as SOPHiA GENETICS, to deliver on the promise of integrated cancer care by bringing insights across multiple diagnostic modalities with the goal of better targeting and matching treatments to each patient’s cancer type, helping to ensure more effective and personalized treatment. Through the acquisition of Zionexa, the company is advancing precision diagnostics and impacting clinical care by commercializing innovative molecular imaging agents.

Furthermore, GE Healthcare offers deep industry expertise, an ability to merge clinical and data science and a breadth of solutions across pharmaceutical diagnostics, cyclotrons, chemistry synthesis, PET/CT, PET/MR, nuclear medicine, advanced digital solutions, and pharmaceutical partnerships – all to help clinicians enhance patient care from discovery to diagnosis to treatment.

Using input from clinical partners, GE Healthcare has designed technologies and digital solutions to keep up with the ever-changing challenges that exist in the imaging world. The Revolution Apex platform, for example, is designed with advanced technologies intended to:

  • Support one-beat cardiac imaging with motion management;
  • Update their service line from a 40 mm detector and 0.28 second rotation speed up to a 160 mm detector and 0.23 second per rotation speed (FDA 510(k) pending) xi,xii ; and
  • Reduce contrast dose up to 33% potentially.

“I'm a fan of the new Apex [platform] system and all the possibilities around it. For us, it's a big win,” said Johan de Mey, MD, PhD, Chair of Radiology at the Universitair Ziekenhuis, Brussels, Belgium. “In the past, we kept machines as long as possible, and we upgraded them with software. But if the hardware was obsolete, we removed it from the hospital. With the Apex, we have a platform with the latest technology and can easily upgrade as our clinical practice evolves.”

Altogether, GE Healthcare is a partner of choice to thousands of healthcare providers, medical technology innovators, and digital start-ups around the world.

About GE Healthcare

GE Healthcare is the $17 billion* healthcare business of GE. As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world. On November 9, 2021, GE announced plans to spin-off GE Healthcare to create a pure-play company at the center of precision health in early 2023.


The European approvals of Glybera in 2012 and Strimvelis in 2016 seem likely to be the vanguard of the therapeutic revolution heralded by the decoding of the human genome. Both of these treatments originated from academic centers of excellence and became the subjects of agreements with pharmaceutical companies Uniqure/Chiesi and GSK, respectively with the experience to navigate the manufacturing infrastructure and regulatory approvals processes that led to the products’ commercialization. The EMA has indicated the level of follow-up it expects to see for these patients, and the FDA’s perspective will likely be revealed with the first US approvals of gene therapies anticipated in 2017.

Related News


Integra Community Care Network Partners is Building the Future of Community Healthcare on the Innovaccer Health Cloud

Integra Community Care, Innovaccer | May 12, 2021

Integra Community Care Network, LLC, a leading Rhode Island-based Accountable Care Organization, has collaborated with Innovaccer Inc., a leading healthcare technology firm, to use the Innovaccer Health Cloud to scale their population health management platform to additional providers, healthcare professionals, and communities in New England. Integra will be able to connect all of the data systems to make medical records more usable and useful. Integra will use the Innovaccer Health Cloud to ingest, aggregate, and normalize healthcare data across systems and settings, resulting in unified patient records and actionable insights that enhance clinical and financial, and operational goals. Integra will gain access to the insights through the Innovaccer Health Cloud's customizable dashboards. With these dashboards, Integra will be able to track its performance on various metrics and refine its activities. Innovaccer's platform supports FHIR APIs and is compliant with the most recent FHIR v4.0.1 version, allowing Integra to share data across the network smoothly and achieve true interoperability. Integra will be able to spot care gaps and engage the network providers with real-time updates with the point-of-care alerts on the Innovaccer Health Cloud. The Innovaccer Health Cloud will also assist network providers in assigning the required care management pathways for patient populations and personalizing healthcare experiences for their patients through outreach and engagement strategies. About Integra Community Care Network, LLC Integra Community Care Network is the state of Rhode Island's largest accountable care organization, representing over 150,000 residents.Integra offers a collaborative team of hospitals, doctors, nurses, social workers, community health workers, and pharmacists who work together to strengthen the community's health and well-being. The Integra network has been recognized locally and nationally for providing high-quality, cost-effective care through teamwork, care coordination, and a focus on preventative health and wellness. Integra is made up of Care New England Health System providers and other healthcare professionals, as well as Rhode Island Primary Care Physicians Corporation, and South County Health. About Innovaccer Innovaccer Inc. is a leading healthcare technology company headquartered in San Francisco that is dedicated to improving healthcare as a whole. The Innovaccer Health Cloud unifies patient data across systems and settings, enabling healthcare organizations to develop scalable, modern applications that improve clinical, operational, and financial outcomes. Innovaccer's solutions have been deployed in over 1,000 care settings across the United States, allowing over 37,000 providers to improve care delivery and collaborate with payers and life sciences firms. Innovaccer has assisted organizations in integrating medical records for over 24 million people, resulting in over $600 million in savings..Innovaccer has been named a Best in KLAS vendor in population health management for 2021, as well as the No. 1 customer-rated vendor by Black Book.

Read More


Blue Health Intelligence Collaborates with AnalyticsIQ to Better Understand the National Health Disparities

Blue Health Intelligence | May 04, 2021

Blue Health Intelligence® (BHI®) declared today a partnership with AnalyticsIQ to expand BHI's rich healthcare information with race and nationality data. The partnership will add 13 identity and language-related information components to BHI's huge, longitudinal database of medical and pharmacy claims for a great many special Americans to grow public investigation and covering health variations. Coronavirus's unbalanced effect has uncovered long-standing healthcare disparities. Governments and strategy bodies have dispatched new drives requiring or urging partners to all the more likely location fundamental social determinants of health (SDOH) when planning and conveying administrations. "We are eager to work with AnalyticsIQ," said Swati Abbott, CEO of BHI. "By safely connecting AnalyticsIQ's identity and language-related information with BHI's tremendous public cases informational index at a part level, BHI and AnalyticsIQ will want to analyze healthcare access, diverse consideration measurements, and results across different ethnic populaces. This capacity will empower us to help key healthcare partners fill in missing data expected to deliver exceptionally exact and versatile bits of knowledge. When combined with BHI's current SDOH information and patent-forthcoming prescient and prescriptive models, BHI can likewise additionally uphold healthcare program enhancements, exploration, and local area partnerships." "We are excited to band together with BHI in its work to improve health results across the U.S.," said Dave Kelly, CEO of AnalyticsIQ. "The requirement for and utilization of solid information and analytics has detonated in the healthcare business on account of its capacity to permit health plans, suppliers, and managers to learn and act rapidly on improving the existences of people and patients, everything being equal. We are glad to help work with the basic experiences expected to get this going." Both BHI and AnalyticsIQ are essential for the Datavant environment. Datavant's innovation de-recognizes healthcare information, eliminating distinguishing data while as yet empowering information to be connected to other informational collections. This ensures patient security while as yet taking into consideration progressed analytics. About Blue Health Intelligence Blue Health Intelligence® (BHI®) is one of the country's transcendent healthcare information convenors. Our information-driven bits of knowledge enable healthcare associations to improve care, diminish costs, and streamline execution. BHI's group of information investigators, clinicians, IT specialists, and business pioneers give analytics, programming as-a-administration, and top to bottom counseling to payers, suppliers, managers, medical gadget organizations, and other healthcare partners. BHI is an autonomous licensee of the Blue Cross Blue Shield Association and conveys the business trademark of Health Intelligence Company, LLC. About AnalyticsIQ AnalyticsIQ is the main prescient analytics and promoting information trailblazer. We are the main information organization to reliably mix intellectual brain research with refined information science to help B2C and B2B advertisers see how and why people settle on choices whether or not they are at home or work. Our precise and extensive PeopleCore and BusinessCore databases give unmatched experiences to publicists, organizations innovation organizations, and healthcare suppliers. AnalyticsIQ information helps blue-chip brands fuel customized encounters across channels including post-office-based mail, email, on the web, versatile, and TV. About Datavant Datavant's main goal is to associate the world's health information to improve patient results. Datavant attempts to lessen the erosion of information sharing across the healthcare business by building innovation that secures the protection of patients while supporting the linkage of de-recognized patient records across datasets. Datavant is settled in San Francisco.

Read More


SyMap Medical Ltd. Announces its Strategic Collaboration with Pythagoras Medical Enhancing and Consolidating the Patent Portfolio

SyMap | December 30, 2021

SyMap Medical Ltd (SyMap) announced its strategic collaboration with Pythagoras Medical. With this win-win collaboration, SyMap has full rights to utilize all assets of Pythagoras, including their Renal Nerve Mapping System (ConfidenHT™, CE Mark Approval,) patents, trademarks and expertise. This collaboration will further enhance and consolidate the patent portfolio of SyMap and ensure the leading position of SyMap in the domain of Renal Denervation (RDN). SyMap is focused on developing revolutionary device therapies for the unmet clinical needs of cardiovascular and pulmonary diseases, including hypertension, heart failure, arrhythmia, asthma and early-stage lung cancer. The company, co-founded by Dr. Jie Wang and Mr. Kewen Jin, is based in bioBAY, located in Suzhou, China. Dr. Wang has a long track record of academic research and entrepreneurship. He is a faculty member of the College of Physicians & Surgeons of Columbia University, professor at the Jiangsu Province Hospital and is the former Dean of Nanjing University's medical school. He has participated in the development of RDN since the technology's infant stages via Ardian Inc. SyMap is conducting two pivotal trials in China: the first is the SMART Studyusing the SyMapCath I™ Catheter/SYMPIONEER S1™ RF system for the treatment of uncontrolled hypertension. This system is based on proprietary technology and is able to map renal nerves for selective renal sympathetic denervation as well as provide feedback for physicians before, during, and after the procedure. The second trial is the BATA Studywhich assesses the efficacy and safety of the Elation™ system to treat severe asthma via bronchial radiofrequency ablations. Both studies are executed by leading clinical investigators and are guided by well-known international experts who serve on the company's Scientific Advisory Boards. Both systems have been granted "Green Channel Device" status by China's regulatory agency. Pythagoras Medical is a cutting-edge medical device company established by Rainbow Medical, Israel's premier medical device investment group. The company is developing a platform for intra-arterial nerve mapping using an electrical stimulation approach for hypertension. Its ConfidenHT™ System has received CE Mark in EU countries.

Read More


The European approvals of Glybera in 2012 and Strimvelis in 2016 seem likely to be the vanguard of the therapeutic revolution heralded by the decoding of the human genome. Both of these treatments originated from academic centers of excellence and became the subjects of agreements with pharmaceutical companies Uniqure/Chiesi and GSK, respectively with the experience to navigate the manufacturing infrastructure and regulatory approvals processes that led to the products’ commercialization. The EMA has indicated the level of follow-up it expects to see for these patients, and the FDA’s perspective will likely be revealed with the first US approvals of gene therapies anticipated in 2017.